+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Rheumatics Market by Drug Class, Route Of Administration, Type, Disease Type, Distribution Channel - Global Forecast to 2030- Product Image
Anti-Rheumatics Market by Drug Class, Route Of Administration, Type, Disease Type, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Anti-Rheumatics Market by Drug Class, Route Of Administration, Type, Disease Type, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014950
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anti-rheumatics market is evolving rapidly in response to scientific advances, regulatory shifts, and the rise of value-based healthcare models. Senior decision-makers operate in a highly competitive landscape where innovation, access, and cost containment must be balanced to drive sustainable business growth.

Market Snapshot: Anti-Rheumatics Market Overview

The Anti-Rheumatics Market grew from USD 96.56 billion in 2024 to USD 101.95 billion in 2025. It is expected to continue growing at a CAGR of 5.71%, reaching USD 134.77 billion by 2030. This performance reflects the combined effects of innovative therapies, refined treatment paradigms, and evolving commercial strategies. Segment growth is led by biologic and targeted treatments, with digital health integration and regional manufacturing shifts further shaping market direction.

Scope & Segmentation

This comprehensive report analyzes the anti-rheumatics market using a robust segmentation framework and examines key external forces driving change.

  • Drug Classes: Includes corticosteroids, disease modifying anti-rheumatics drugs (covering biologic DMARDs, conventional DMARDs, and targeted synthetic DMARDs), nonsteroidal anti-inflammatory drugs, and uric acid drugs.
  • Route of Administration: Evaluates injectable, oral, and topical formats, factoring in infrastructure and patient adherence considerations.
  • Product Types: Differentiates over-the-counter drugs and prescription-based drugs for tailored engagement strategies.
  • Disease Indications: Encompasses ankylosing spondylitis, bursitis, gout, juvenile idiopathic arthritis, osteoarthritis, osteoporosis, polymyalgia rheumatica, psoriatic arthritis, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, systemic sclerosis/scleroderma, and tendinitis.
  • Distribution Channels: Assesses impact of hospital pharmacies, online pharmacies, and retail pharmacies on product accessibility and supply chain optimization.
  • Geographical Regions: Covers Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key markets such as the United Kingdom, Germany, France, Russia, and others), and Asia-Pacific (including China, India, Japan, Australia, South Korea, and additional high-growth countries).
  • Leading Innovators: Profiles organizations driving the market, including multinational pharmaceutical firms and specialty biotechs focused on novel mechanisms and biosimilars.

Key Takeaways for Decision-Makers

  • Therapeutic innovation is redefining standards of care, with emphasis on targeted synthetic and biologic DMARDs coexisting alongside established therapies to ensure comprehensive treatment portfolios.
  • Integration of digital health solutions, such as telemedicine and wearable monitoring, is enhancing clinical trial efficiency and real-world evidence generation, supporting faster regulatory and payer decision-making.
  • Value-based contracting and risk-sharing models are influencing reimbursement approaches, requiring robust outcomes data and new collaboration strategies for manufacturers and payers.
  • Segmentation by indication and administration route allows for tailored product positioning, responding to patient and prescriber preferences as well as local policy conditions.
  • Regional market disparities highlight the importance of scalable go-to-market strategies, ranging from biosimilar adoption in emerging markets to premium biologic launches in mature economies.
  • Mid-sized and niche biotechs continue to gain traction through focus on rare and underserved indications, leveraging biomarker-driven approaches to secure expedited pathways and competitive pricing.

2025 US Tariff Impact

The introduction of new US tariffs on pharmaceutical imports in 2025 is prompting market recalibration across the supply chain. Increased import costs for active ingredients and finished products are leading manufacturers to evaluate North American production facilities, benefiting from local regulatory incentives. Distributors are adopting duty optimization strategies, while manufacturers balance price competitiveness and profitability in negotiations with payers and pharmacy benefit managers. Industry collaboration and strategic lobbying are ongoing to protect access to essential anti-rheumatics, minimizing patient disruption.

Methodology & Data Sources

This report is based on a robust multi-tiered research process, combining secondary research from peer-reviewed sources, regulatory databases, and market intelligence platforms with in-depth primary interviews from across the sector. Quantitative insights are validated by scenario modeling and expert review, ensuring credible guidance for commercial strategy.

Why This Report Matters

  • Delivers actionable segmentation and competitor benchmarking for optimizing market entry, product positioning, and resource allocation.
  • Equips senior leaders with strategic insights on policy impacts, regional opportunities, and future-ready commercial models in the anti-rheumatics market.
  • Supports informed investment, partnership, and portfolio-management decisions with up-to-date, analyst-validated data to reduce risk amid uncertainty.

Conclusion

Amid technological advances, regulatory change, and shifting reimbursement models, the anti-rheumatics market demands adaptive strategies. This report provides the clarity needed to navigate complexity, capitalize on emerging trends, and drive actionable growth initiatives.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Rheumatics Market, by Drug Class
8.1. Introduction
8.2. Corticosteroids
8.3. Disease Modifying Anti-rheumatics Drugs
8.3.1. Biologic DMARDs
8.3.1.1. B-cell Inhibitors
8.3.1.2. Interleukin Inhibitors
8.3.1.3. T-cell Co-stimulation Modulators
8.3.1.4. Tumor Necrosis Factor (TNF) Inhibitors
8.3.2. Conventional DMARDs
8.3.3. Targeted Synthetic DMARDs
8.4. Nonsteroidal Anti-inflammatory Drugs
8.5. Uric Acid Drugs
9. Anti-Rheumatics Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.3. Oral
9.4. Topical
10. Anti-Rheumatics Market, by Type
10.1. Introduction
10.2. Over-the-Counter Drugs
10.3. Prescription-Based Drugs
11. Anti-Rheumatics Market, by Disease Type
11.1. Introduction
11.2. Ankylosing Spondylitis
11.3. Bursitis
11.4. Gout
11.5. Juvenile Idiopathic Arthritis
11.6. Osteoarthritis
11.7. Osteoporosis
11.8. Polymyalgia Rheumatica
11.9. Psoriatic Arthritis
11.10. Rheumatoid Arthritis
11.11. Sjögren's Syndrome
11.12. Systemic Lupus Erythematosus
11.13. Systemic Sclerosis/Scleroderma
11.14. Tendinitis
12. Anti-Rheumatics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Anti-Rheumatics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Anti-Rheumatics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Anti-Rheumatics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Alvotech
16.3.3. Amgen Inc.
16.3.4. ANI Pharmaceuticals, Inc.
16.3.5. AstraZeneca PLC
16.3.6. Bayer AG
16.3.7. Biogen Inc.
16.3.8. Bristol-Myers Squibb Company
16.3.9. C. H. Boehringer Sohn AG & Co. KG
16.3.10. DeepCure
16.3.11. Eisai Co., Ltd.
16.3.12. Eli Lilly and Company
16.3.13. F. Hoffmann-La Roche Ltd.
16.3.14. Fresenius Kabi AG
16.3.15. Galapagos NV
16.3.16. Gilead Sciences, Inc.
16.3.17. GlaxoSmithKline PLC
16.3.18. ILTOO Pharma SAS
16.3.19. Johnson & Johnson Services Inc.
16.3.20. medac GmbH
16.3.21. Merck & Co., Inc.
16.3.22. Novartis AG
16.3.23. Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
16.3.24. Pfizer, Inc.
16.3.25. Regeneron Pharmaceuticals, Inc.
16.3.26. Sanofi SA
16.3.27. Takeda Pharmaceutical Company Limited
16.3.28. Teva Pharmaceutical Industries Ltd.
16.3.29. UCB S.A.
16.3.30. Vertex Pharmaceuticals Incorporated
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTI-RHEUMATICS MARKET MULTI-CURRENCY
FIGURE 2. ANTI-RHEUMATICS MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-RHEUMATICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTI-RHEUMATICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-RHEUMATICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY B-CELL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY T-CELL CO-STIMULATION MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TUMOR NECROSIS FACTOR (TNF) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TARGETED SYNTHETIC DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY URIC ACID DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PRESCRIPTION-BASED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY BURSITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY POLYMYALGIA RHEUMATICA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SJÖGREN'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY SYSTEMIC SCLEROSIS/SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY TENDINITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTI-RHEUMATICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTI-RHEUMATICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 63. CANADA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 64. CANADA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 106. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 107. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 110. GERMANY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 113. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 114. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 117. FRANCE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 127. ITALY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 128. ITALY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. ITALY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 130. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 134. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 135. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 138. SPAIN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 148. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 155. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 156. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 162. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 163. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 166. DENMARK ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 175. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 176. QATAR ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 177. QATAR ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. QATAR ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 180. QATAR ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 183. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 184. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 187. FINLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 190. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 191. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 194. SWEDEN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 197. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 198. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 204. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 205. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 208. EGYPT ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 210. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 211. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 212. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 214. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 215. TURKEY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 222. ISRAEL ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 224. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 225. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 226. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 228. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 229. NORWAY ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 231. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 232. POLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 233. POLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. POLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 235. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 236. POLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 238. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 239. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 240. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 242. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 243. SWITZERLAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC ANTI-RHEUMATICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 252. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 253. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 254. CHINA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 255. CHINA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. CHINA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 257. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 258. CHINA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 261. INDIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 262. INDIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. INDIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 264. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 265. INDIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 267. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 268. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 269. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 271. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 272. JAPAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 282. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 283. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 285. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 286. SOUTH KOREA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 289. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 290. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 292. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 293. INDONESIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 295. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 296. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 297. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 299. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 300. THAILAND ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 303. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 304. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 306. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 307. PHILIPPINES ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 310. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 311. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 313. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 314. MALAYSIA ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 317. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 318. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 319. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 320. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 321. SINGAPORE ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 322. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 323. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 324. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 325. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 326. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 327. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 328. VIETNAM ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 330. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE MODIFYING ANTI-RHEUMATICS DRUGS, 2018-2030 (USD MILLION)
TABLE 331. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY BIOLOGIC DMARDS, 2018-2030 (USD MILLION)
TABLE 332. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 334. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 335. TAIWAN ANTI-RHEUMATICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 336. ANTI-RHEUMATICS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 337. ANTI-RHEUMATICS MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-Rheumatics market report include:
  • AbbVie Inc.
  • Alvotech
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • C. H. Boehringer Sohn AG & Co. KG
  • DeepCure
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • ILTOO Pharma SAS
  • Johnson & Johnson Services Inc.
  • medac GmbH
  • Merck & Co., Inc.
  • Novartis AG
  • Otter Pharmaceuticals, LLC by Assertio Holdings, Inc.
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 101.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 134.77 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Anti-Rheumatics Market Report by Type, Route of Drug Administration, Distribution Channel, and Region 2024-2032 - Product Image

Anti-Rheumatics Market Report by Type, Route of Drug Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 140 Pages
  • Global
From
Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Rheumatology Therapeutics Market by Therapeutic Class, Molecule Type, Indication, Route of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030 - Product Image

Rheumatology Therapeutics Market by Therapeutic Class, Molecule Type, Indication, Route of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • Report
  • 195 Pages
  • Global
From
Rheumatology Therapeutics - Global Strategic Business Report - Product Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Psoriatic Arthritis Therapeutics - Global Strategic Business Report - Product Image

Psoriatic Arthritis Therapeutics - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.